Lee succeeds Steve Tregay, Ph.D., who after more than a decade as founder and CEO, will transition to the role of senior advisor to the CEO.
Lee, an industry veteran and champion for patients, joins Forma with over 25 years of global experience in product development and commercial leadership across a range of therapeutic areas within the biotech and pharmaceutical industry.
Most recently, Lee served as senior vice president, Global Product Strategy and Therapeutic Area Head for the Immunology, Ophthalmology and Infectious Diseases at Genentech, a member of the Roche Group.
Lee's thirteen-year career at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients.
Most recently, as senior vice president, Global Product Strategy, he was responsible for driving development and commercial strategy for a portfolio of molecules in development and for global in-line product sales of more than USD 11bn.
Previously, as vice president of the HER2/Breast Cancer Franchise, Lee was responsible for the US P and L for Herceptin, Perjeta and Kadcyla, driving revenues over USD 4bn and launching the first HER2 neoadjuvant indication shaping a new market and treatment paradigm for early HER2 breast cancer patients.
As vice president of Oral Oncolytics, Lee held P and L responsibility for Tarceva, Zelboraf, Erivedge and Xeloda, advancing personalised medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma, and establishing a new treatment option for patients with advanced basal cell carcinoma.
Other roles at Genentech included Franchise Head, Transplant and Tamiflu as well as director of Marketing for Ophthalmology and Respiratory.
Prior to joining Genentech, Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development.
He previously served on the board of the Genentech Foundation.
Forma Therapeutics develops medicines addressing oncology, inflammation, neurodegeneration and other serious diseases.
The company's R and D team drives discovery and clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial